Study of heart pump support after heart attack
Part of Heart & circulation clinical trials.
This study looks at how well a temporary heart pump helps people who have had a heart attack complicated by cardiogenic shock. The pump supports the heart while doctors restore blood flow, which may improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a heart attack (STEMI or NSTEMI).
- You have signs of cardiogenic shock, like low blood pressure, cool limbs, or high lactate levels.
- You are already receiving support from a transvalvular heart pump.
- You are having a procedure to open blocked arteries within 12 hours of arriving at the hospital.
- You or your legal representative can give consent to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a small mechanical pump inside the heart plus careful monitoring with a special catheter can help people in shock after a heart attack. It compares this approach to standard care, aiming to improve survival and recovery.
This study tracks how well people with cardiogenic shock (a life-threatening drop in blood flow after a heart attack or heart failure worsening) do when treated with modern support devices and medicines.
This trial tests a new heart pump device (CorVad) to support the heart in people who are in cardiogenic shock after a heart attack. It may help stabilize blood pressure and improve blood flow, potentially giving the heart time to recover.
This trial is testing different approaches (medications and mechanical support) to help people with acute heart failure and cardiogenic shock (a sudden drop in the heart's pumping ability). It looks at how well these treatments work in a network of hospitals to improve outcomes.
This study looks at people with a severe type of shock that affects both the heart and blood vessels, treated in the intensive care unit. It aims to understand how these patients recover and what factors impact their survival.
This study examines detailed data from patients who received an Impella 5.5 heart pump to treat cardiogenic shock—a life-threatening condition where the heart cannot pump enough blood. Researchers use advanced computer analysis to understand what helps patients recover best.
Hear when a new Cardiogenic Shock Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.